Oral Administration

SLN dispersions were recommended to be transformed to a dry dosage form, being most convenient for the patient (e.g., tablet, pellets, or gelatine capsules). Despite having SLN particle dispersions up to 30% lipid content, still 70% water remains to be removed, which is a relatively high amount in a drying process. Approaches to obtain dry products are the use of lipid particle dispersions as a granulation fluid in tabletting, as a wetting agent in pellet production, or direct filling of nonaqueous SLN dispersions into soft gelatine capsules. These problems have been drastically reduced when producing highly concentrated NLC dispersions, for example, 40 or 50%.

The filling of gelatine capsules with nonaqueous SLN dispersions could generate another problem, which means insufficient loading capacity of the capsule for the drug. The gelatine capsule contains only a certain percentage of lipid particles, and the lipid particles themselves only a certain percentage of the drug. From this, one encountered dosing problems when having single drug doses of about 25 mg and more. This is not at all or is less of a problem when processing highly concentrated NLC dispersions.

0 0

Post a comment